Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AiRuiKa (camrelizumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

CG Invites, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax

Drug class:

PD1 inhibitor

Related drugs:

‹

pembrolizumab (727)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (7)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

ivonescimab (3)

finotonlimab (0)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

nivolumab and hyaluronidase-nvhy (0)

PD-1-KO-T cell injection (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	camrelizumab Sensitive: A2 - Guideline camrelizumab Sensitive : A2	camrelizumab Sensitive: A2 - Guideline camrelizumab Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab Sensitive: B - Late Trials camrelizumab Sensitive : B	camrelizumab Sensitive: B - Late Trials camrelizumab Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2